» Articles » PMID: 1362653

Insights into the Mechanisms of Action of the MAO Inhibitors Phenelzine and Tranylcypromine: a Review

Overview
Specialty Psychiatry
Date 1992 Nov 1
PMID 1362653
Citations 26
Authors
Affiliations
Soon will be listed here.
Abstract

Although the non-selective monoamine oxidase inhibitors phenelzine and tranylcypromine have been used for many years, much still remains to be understood about their mechanisms of action. Other factors, in addition to the inhibition of monoamine oxidase and the subsequent elevation of brain levels of the catecholamines and 5-hydroxytryptamine, may contribute to the overall pharmacological profiles of these drugs. This review also considers the effects on brain levels of amino acids and trace amines, uptake and release of neurotransmitter amines at nerve terminals, receptors for amino acids and amines, and enzymes other than monoamine oxidase, including enzymes involved in metabolism of other drugs. The possible contributions of metabolism and stereochemistry to the actions of these monoamine oxidase inhibitors are discussed.

Citing Articles

Design, Synthesis and Biological Evaluation of Novel Ketamine Derivatives as NMDAR Antagonists.

Li S, Wen B, Zhao W, Wang L, Chen X Molecules. 2024; 29(11).

PMID: 38893335 PMC: 11173549. DOI: 10.3390/molecules29112459.


Benefits and Risks of Medications Used in the Management of Hypotension: A Review.

Skylynn T, Abel T, Christopher L, Suliman G, Dominic R, Joel V Cureus. 2024; 16(1):e51608.

PMID: 38313995 PMC: 10837047. DOI: 10.7759/cureus.51608.


Concomitant use of monoamine oxidase inhibitor and tyrosine in parenteral nutrition.

Bharani T, Mogensen K, Rosen J, Gura K, Robinson M Eur J Clin Nutr. 2023; 78(3):274-276.

PMID: 38057413 DOI: 10.1038/s41430-023-01375-8.


Rethinking, reducing, and refining the classical oral tyramine challenge test of monoamine oxidase (MAO) inhibitors.

van Hoogdalem E, Smith K, Hartstra J, Constant J Clin Transl Sci. 2023; 16(10):2058-2069.

PMID: 37596819 PMC: 10582662. DOI: 10.1111/cts.13612.


Epidrugs in the Therapy of Central Nervous System Disorders: A Way to Drive on?.

Gladkova M, Leidmaa E, Anderzhanova E Cells. 2023; 12(11).

PMID: 37296584 PMC: 10253154. DOI: 10.3390/cells12111464.


References
1.
Dyck L, Durden D, Boulton A . Formation of beta-phenylethylamine from the antidepressant, beta-phenylethylhydrazine. Biochem Pharmacol. 1985; 34(11):1925-9. DOI: 10.1016/0006-2952(85)90310-7. View

2.
McManus D, Baker G, Martin I, Greenshaw A, McKenna K . Effects of the antidepressant/antipanic drug phenelzine on GABA concentrations and GABA-transaminase activity in rat brain. Biochem Pharmacol. 1992; 43(11):2486-9. DOI: 10.1016/0006-2952(92)90331-c. View

3.
Baker G, Wong J, Yeung J, Coutts R . Effects of the antidepressant phenelzine on brain levels of gamma-aminobutyric acid (GABA). J Affect Disord. 1991; 21(3):207-11. DOI: 10.1016/0165-0327(91)90041-p. View

4.
Ordway G, Gambarana C, Tejani-Butt S, Areso P, Hauptmann M, Frazer A . Preferential reduction of binding of 125I-iodopindolol to beta-1 adrenoceptors in the amygdala of rat after antidepressant treatments. J Pharmacol Exp Ther. 1991; 257(2):681-90. View

5.
Yu P, Davis B, Durden D . Enzymatic N-methylation of phenelzine catalyzed by methyltransferases from adrenal and other tissues. Drug Metab Dispos. 1991; 19(4):830-4. View